Jeffrey Wolf, MD, on Implications of Findings from Multiple Myeloma Study Presented at ASH
Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.
Jeffrey Wolf, MD, of the University of California San Francisco, discussed with CancerNetwork the implications of the results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma presented at the 2020 American Society of Hematology (ASH) Annual Meeting.
Transcription:
So, what we discovered when we looked at those 58 people who had decisions made, and we compared it to the other patients where decisions weren’t made, we found that there were more people that achieved MRD-zero because the change allowed them to get to MRD-zero. And, for patients [where] their decision was controlled longer, that is the progression-free survival, improved significantly from 75 months to 97 months. So, we believe that by measuring MRD and using it to make decisions, you can achieve better outcomes for your patient.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
